G1 Therapeutics falls 24% after topline data from trilaciclib study

Shares of G1 Therapeutics, are down 23.5% or $6.75 per share to $22 per share in after-hours trading. after announcing the Objective response rate, ORR, in its lung cancer study was, placebo: n=6/26, 23.1%; trilaciclib: n=4/30, 13.3%.

https://thefly.com/landingPageNews.php?id=2839601